Alexion Pharmaceuticals, Inc. (ALXN) Q4 2015 Earnings Conference Call February 3, 2016 10:00 AM ET
Executives
Elena Ridloff - Vice President, Investor Relations
David Hallal - Chief Executive Officer
Vikas Sinha - Executive Vice President and Chief Financial Officer
Carsten Thiel - Executive Vice President and Chief Commercial Officer
Martin Mackay - Executive Vice President and Global Head, Research and Development
Saqib Islam - Executive Vice President, Chief Strategy and Portfolio Officer
Julie O'Neill - Executive Vice President, Global Operations
Analysts
Eric Schmidt - Cowen and Company
Anupam Rama - JPMorgan
Ying Huang - Bank of America Merrill Lynch
Matt Roden - UBS
Yatin Suneja - SunTrust
Chris Raymond - Raymond James
Cyrus Mahloudji - Morgan Stanley
Geoff Meacham - Barclays
Terence Flynn - Goldman Sachs
Alethia Young - Credit Suisse.
Operator
Good day, everyone, and welcome to today's Alexion Pharmaceuticals Incorporated fourth quarter and full year 2015 conference call. Just as a reminder, today's call is being recorded. For opening remarks and introductions, I would like to turn the call over to Elena Ridloff, Vice President, Investor Relations. Please go ahead, ma'am.
Elena Ridloff
Thank you, Sarah. Good morning and thank you for joining us today to discuss Alexion's performance for the fourth quarter and full year 2015 and our plans for 2016.
Today's call will be led by David Hallal, our CEO. David will start the call with an overview of our global performance and be joined by Vikas Sinha, our Chief Financial Officer; Carsten Thiel, our Chief Commercial Officer; and Martin MacKay, our Global Head of R&D. Also, with us today are Saqib Islam, our Chief Strategy and Portfolio Officer; and Julie O'Neill, our Global Head of Operations.
You can access the webcast slides that will be presented on this call, by going to the Events section of
- Read more current ALXN analysis and news
- View all earnings call transcripts